Mindpeak, a leader in AI-powered pathology solutions, has successfully secured $15.3 million in a Series A funding round. This round was led by ZEISS Ventures and InnoVentureFund, with additional support from AI.FUND and the European Innovation Council Fund.

Even though the company is already cash flow positive, this new investment will help accelerate the commercialization of its innovative technologies in various regions.

With this funding, Mindpeak aims to enhance the development and deployment of its AI solutions, providing pathologists and researchers with faster, more accurate diagnostic tools. The company is focused on revolutionizing cancer diagnostics to ultimately improve patient treatment outcomes.

Mindpeak's AI algorithms are among the first to be integrated into routine clinical diagnostics in the US and EU.

These advanced solutions facilitate automated histological and immunohistochemical tissue analysis, enabling experts to make more informed decisions. To date, Mindpeak's technology has supported over 30,000 patient diagnoses.

Additionally, biopharmaceutical companies are utilizing this AI to predict how effective specific drugs will be in cancer therapy, paving the way for more targeted treatments.

Since its founding in 2018, Mindpeak has made significant strides in digital pathology, expanding its product portfolio to include a wider range of organs, biomarkers, and stains.

Strategic partnerships with leading healthcare organizations, such as Roche, along with positive regulatory developments, have further strengthened its market presence.

This latest funding round positions Mindpeak to continue its rapid innovation in digital pathology, enhancing its role in transforming cancer diagnostics for the better.





Source: businesswire.com

Report Abuse